Naturally occurring cannabinoid CBD (cannabidiol) compounds possess no abuse potential and therefore should not be subject to restrictions under international drug scheduling, recommendations of the World Health Organisation’s Expert Committee on Drug Dependence (ECDD) concluded. “Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions.” The ECDD adds that since the current information does not justify scheduling of cannabidiol; a fuller review of cannabidiol preparations by May 2018 is planned.